{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:45:43Z","timestamp":1792363543536,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003213","name":"Beijing Municipal Education Commission","doi-asserted-by":"publisher","award":["KM202410025015"],"award-info":[{"award-number":["KM202410025015"]}],"id":[{"id":"10.13039\/501100003213","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2023YFC3605000"],"award-info":[{"award-number":["2023YFC3605000"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","award":["QNPY202323"],"award-info":[{"award-number":["QNPY202323"]}],"id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jacl.2025.10.076","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T23:07:24Z","timestamp":1762038444000},"page":"326-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Associations of lipid-lowering drugs with cardiovascular-kidney-metabolic syndrome: A drug-target Mendelian randomization study"],"prefix":"10.1016","volume":"20","author":[{"given":"Mengjin","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoting","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinggang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.10.076_bib0001","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.10.076_bib0002","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.jacc.2024.03.368","article-title":"Prevalence of the cardiovascular-kidney-metabolic syndrome in the United States","volume":"83","author":"Minhas","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.10.076_bib0003","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.10.076_bib0004","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.10.076_bib0005","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.10.076_bib0006","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2025.10.076_bib0007","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR Statement","volume":"326","author":"Skrivankova","year":"2021","journal-title":"Jama"},{"key":"10.1016\/j.jacl.2025.10.076_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacl.2025.10.076_bib0009","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jacl.2025.10.076_bib0010","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/HYPERTENSIONAHA.124.23829","article-title":"Associations of lipid-lowering drugs with blood pressure and fasting glucose: a mendelian randomization study","volume":"82","author":"Song","year":"2025","journal-title":"Hypertension"},{"key":"10.1016\/j.jacl.2025.10.076_bib0011","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.10.076_bib0012","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.10.076_bib0013","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.10.076_bib0014","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00125-015-3528-5","article-title":"Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort","volume":"58","author":"Cederberg","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacl.2025.10.076_bib0015","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2016.14568","article-title":"Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis","volume":"316","author":"Lotta","year":"2016","journal-title":"Jama"},{"key":"10.1016\/j.jacl.2025.10.076_bib0016","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.cmet.2023.12.027","article-title":"Statins aggravate insulin resistance through reduced blood glucagon-like peptide-1 levels in a microbiota-dependent manner","volume":"36","author":"She","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.jacl.2025.10.076_bib0017","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/ndt\/gfl538","volume":"22","author":"Athyros","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacl.2025.10.076_bib0018","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1681\/ASN.2013090965","article-title":"Effects of lowering LDL cholesterol on progression of kidney disease","volume":"25","author":"Haynes","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2025.10.076_bib0019","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1681\/ASN.2022020135","article-title":"Association of rosuvastatin use with risk of hematuria and proteinuria","volume":"33","author":"Shin","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2025.10.076_bib0020","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jgs.19319","article-title":"Effects of statins on kidney function in older adults","volume":"73","author":"Fravel","year":"2025","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jacl.2025.10.076_bib0021","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.10.076_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-511X-14-1","article-title":"Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia","volume":"14","author":"Adachi","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2025.10.076_bib0023","doi-asserted-by":"crossref","first-page":"532","DOI":"10.5551\/jat.10835","article-title":"Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia","volume":"19","author":"Tamaki","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2025.10.076_bib0024","doi-asserted-by":"crossref","first-page":"106","DOI":"10.5551\/jat.1578","article-title":"The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia","volume":"17","author":"Hiramitsu","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2025.10.076_bib0025","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.5551\/jat.12427","article-title":"Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia","volume":"19","author":"Kikuchi","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2025.10.076_bib0026","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/eci.12000","article-title":"Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study","volume":"42","author":"Takase","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacl.2025.10.076_bib0027","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1161\/STROKEAHA.119.027759","article-title":"Stroke prevention with the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis","volume":"51","author":"Giugliano","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.jacl.2025.10.076_bib0028","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2025.10.076_bib0029","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.10.076_bib0030","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.10.076_bib0031","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011581","article-title":"Association of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering therapies and risk of diabetes mellitus: a systematic review and meta-analysis","volume":"8","author":"Khan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.10.076_bib0032","article-title":"Genetic association analysis of lipid-lowering drug target genes in chronic kidney disease","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacl.2025.10.076_bib0033","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","article-title":"Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside","volume":"9","author":"Bao","year":"2024","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.jacl.2025.10.076_bib0034","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.10.076_bib0035","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425004994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425004994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:46:23Z","timestamp":1773917183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425004994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1933287425004994"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.10.076","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations of lipid-lowering drugs with cardiovascular-kidney-metabolic syndrome: A drug-target Mendelian randomization study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.10.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}